Topic:

Venture Capital

Latest Headlines

Latest Headlines

Isarna snags another $7.6M to advance its cancer immunotherapy

After shifting its focus to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates.

Arch Venture swings for a $250M fund to bet on biotechs

Stalwart biotech investor Arch Venture Partners is putting together a $250 million 8th fund, according to a regulatory filing, piling on to the roughly $1.5 billion it currently manages.

Juno wraps up a $176M A round as it hits the gas on its CAR-T contender

A week after the FDA lifted a clinical hold on a trial of its lead cancer candidate, startup Juno Therapeutics has closed its overstuffed $176 million Series A, drawing cash from Arch Venture Partners, Amazon founder Jeff Bezos and others.

Kala reels in $22.5M to get its next-gen eye drops into PhIII

Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.

VC groups put up $165M for a trifecta of biotech rounds

A Detroit-based biotech has landed a $59.5 million round to continue its work on a nucleic acid-based DNAi cancer therapy now in a mid-stage trial. ProNAi Therapeutics CEO Mina Sooch says that's enough cash to get the company through 2016, with plans to pursue partnership talks as well as a discussion with the FDA about potential ways to accelerate the approval process for their lead therapy.

Biotech VCs wager $1.1B in Q1, plus: top 5 rounds

Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.

Biotech upstart grabs $18M to study a new drug to protect pregnancies

A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.

Column Group nears goal line for $250M biotech venture fund

The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.

Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy

Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.

VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex

An Australian biotech company with a mid-stage pain drug is using a new $45 million venture round from a group that includes a pair of marquee international investors to put down U.S. roots in Stamford, CT, as it pushes ahead in the clinic. The Series C brings Spinifex Pharmaceuticals' total raise to $70 million, says CEO Tom McCarthy, with enough money committed to fund operations for the next three years.